Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

Kimberly-Clark (KMB) shares have edged lower in recent trading, catching investors’ attention as the company’s performance trends have lagged over the past month. The stock’s nearly 17% slide in that ...

Kimberly-Clark (NASDAQ:KMB) is making a massive bet but investors aren't sure on how to feel about it. The maker of Kleenex ...

Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...

Kimberly-Clark shares declined marginally in the premarket session on Tuesday, after a sharp drop the previous day. ・The ...

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

AM ET, the S&P 500 gained 10.83 points, or 0.16%, the Nasdaq Composite gained 119.50 points, or 0.51%, and the Dow Jones ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

In this piece, we will look at the stocks Jim Cramer discussed.